<a href="https://laohu8.com/S/PHIO">Phio Pharmaceuticals</a> Announces Positive Interim Results in Phase 1b Clinical Trial of INTASYL Compound PH-762 for Skin Cancer Treatment
Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, scheduled for June 30, 2025, will feature a presentation by CEO and Chairman Robert Bitterman, who will provide an update on the company's proprietary INTASYL® siRNA technology. The presentation will include progress reports on the ongoing clinical trial of the lead compound PH-762, which is being developed for the treatment of skin cancers. Positive interim safety and efficacy results have already been reported from the Phase 1b dose escalation clinical trial of PH-762. The presentation and live Q&A session can be accessed via the Renmark Financial Communications Inc. website, with a replay available post-event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 256503) on June 24, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。